Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SMZ1 and Ranibizumab in Neovascular Age-related Macular Degeneration
NCT07695207Phase 3Recruiting
- Sponsor
- Sangmyung Innovation
- Start
- Sep 2025
- Primary completion
- Dec 2027
- Countries
- 1
01
Overview
A Phase 3 trial of spironolactone in neovascular age-related macular degeneration (NVAMD), sponsored by Sangmyung Innovation. Started Sep 2025; status: recruiting.
02
Drugs
spironolactone
03
Conditions
neovascular age-related macular degeneration (NVAMD)
Beyond the preview
Go deeper on NCT07695207.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07695207.